3 Penny Stocks In US With Market Caps Below $300M

As the U.S. stock market faces a challenging period with major indexes declining for the second consecutive week, investors are navigating an environment shaped by rising Treasury yields and robust economic data. Amidst this backdrop, penny stocks—despite their somewhat outdated moniker—remain a relevant area of interest for those seeking unique investment opportunities. These smaller or newer companies can offer growth potential at lower price points, especially when they possess strong financials and solid fundamentals.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
Inter & Co (NasdaqGS:INTR)	$4.26	$1.87B	★★★★☆☆
QuantaSing Group (NasdaqGM:QSG)	$3.08	$100.69M	★★★★★★
BAB (OTCPK:BABB)	$0.84525	$6.14M	★★★★★★
Kiora Pharmaceuticals (NasdaqCM:KPRX)	$3.5235	$10.57M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.33	$12.14M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
BTCS (NasdaqCM:BTCS)	$2.54	$44.07M	★★★★★★
Zynerba Pharmaceuticals (NasdaqCM:ZYNE)	$1.30	$65.6M	★★★★★☆
Smith Micro Software (NasdaqCM:SMSI)	$1.36	$24.12M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.9599	$86.33M	★★★★★☆

Click here to see the full list of 734 stocks from our US Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Genenta Science (NasdaqCM:GNTA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Genenta Science S.p.A. is a clinical-stage biotechnology company focused on developing hematopoietic stem cell gene therapies for treating solid tumors in Italy, with a market cap of $86.88 million.

Operations: There are no reported revenue segments for the clinical-stage biotechnology company focused on developing hematopoietic stem cell gene therapies for treating solid tumors.

Market Cap: $86.88M

Genenta Science, a clinical-stage biotechnology company, is pre-revenue and unprofitable, with losses increasing annually by 21.9% over the past five years. Despite this, it maintains a strong financial position with short-term assets of €18.6 million exceeding its liabilities and no debt for the past five years. The company has secured a cash runway for nearly three years under current conditions. Recent developments include an enhanced partnership with AGC Biologics to bolster manufacturing capabilities and ongoing trials in metastatic Renal Cell Cancer and Glioblastoma Multiforme studies, projecting production of 27 autologous drug products in 2025.

• Take a closer look at Genenta Science's potential here in our financial health report.
• Review our growth performance report to gain insights into Genenta Science's future.

Tiziana Life Sciences (NasdaqCM:TLSA)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Tiziana Life Sciences Ltd is a biotechnology company that focuses on discovering and developing molecules to treat human diseases in oncology and immunology in the United States, with a market cap of $91.63 million.

Operations: Currently, Tiziana Life Sciences Ltd does not report any revenue segments.

Market Cap: $91.63M

Tiziana Life Sciences, a pre-revenue biotechnology firm with a market cap of US$91.63 million, is actively advancing its clinical programs despite financial challenges. The company has achieved significant milestones in developing intranasal foralumab for Alzheimer's and multiple sclerosis, backed by a US$4 million NIH grant. However, Tiziana faces liquidity constraints with short-term assets of US$7.8 million against liabilities of US$9.1 million and has recently raised capital through equity offerings to extend its cash runway beyond two months. The management team is relatively new, averaging 1.2 years in tenure, while the board remains experienced with nine years on average.

• Get an in-depth perspective on Tiziana Life Sciences' performance by reading our balance sheet health report here.
• Review our historical performance report to gain insights into Tiziana Life Sciences' track record.

Perfect (NYSE:PERF)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Perfect Corp. is an artificial intelligence software as a service company that offers AI and AR-powered solutions for the beauty, fashion, and skincare industries globally, with a market cap of approximately $275 million.

Operations: The company generates revenue of $58.45 million from its Internet Software & Services segment.

Market Cap: $274.99M

Perfect Corp., with a market cap of US$275 million, is leveraging AI and AR technologies in the beauty sector, generating US$58.45 million in revenue. The company recently showcased its innovations at CES 2025, emphasizing its AI-driven solutions like Perfect GPT and AI Skin Analysis. Despite high share price volatility and a relatively new board with an average tenure of 2.3 years, Perfect Corp.'s financial health is robust with short-term assets exceeding liabilities significantly, and no debt burden to manage. While profitable this year, its return on equity remains low at 3.7%, indicating room for improvement in profitability metrics.

• Click here and access our complete financial health analysis report to understand the dynamics of Perfect.
• Assess Perfect's future earnings estimates with our detailed growth reports.

Key Takeaways

• Unlock more gems! Our US Penny Stocks screener has unearthed 731 more companies for you to explore.Click here to unveil our expertly curated list of 734 US Penny Stocks.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com